Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 5;29(12):1993-1996.
doi: 10.1093/ibd/izad053.

Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases

Affiliations
Review

Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases

Ghadeer K Dawwas et al. Inflamm Bowel Dis. .

Abstract

Background: To facilitate inflammatory bowel disease (IBD) research in the United States, we developed and validated claims-based definitions to identify incident and prevalent IBD diagnoses using administrative healthcare claims data among multiple payers.

Methods: We used data from Medicare, Medicaid, and the HealthCore Integrated Research Database (Anthem commercial and Medicare Advantage claims). The gold standard for validation was review of medical records. We evaluated 1 incidence and 4 prevalence algorithms based on a combination of International Classification of Diseases codes, National Drug Codes, and Current Procedural Terminology codes. The claims-based incident diagnosis date needed to be within ±90 days of that recorded in the medical record to be valid.

Results: We reviewed 111 charts of patients with a potentially incident diagnosis. The positive predictive value (PPV) of the claims algorithm was 91% (95% confidence interval [CI], 81%-97%). We reviewed 332 charts to validate prevalent case definition algorithms. The PPV was 94% (95% CI, 86%-98%) for ≥2 IBD diagnoses and presence of prescriptions for IBD medications, 92% (95% CI, 85%-97%) for ≥2 diagnoses without any medications, 78% (95% CI, 67%-87%) for a single diagnosis and presence of an IBD medication, and 35% (95% CI, 25%-46%) for 1 physician diagnosis and no IBD medications.

Conclusions: Through a combination of diagnosis, procedural, and medication codes in insurance claims data, we were able to identify incident and prevalent IBD cases with high accuracy. These algorithms can be useful for the ascertainment of IBD cases in future studies.

Keywords: IBD; ICD; epidemiology; observational study; validation.

PubMed Disclaimer

Conflict of interest statement

G.K.D. has received funding from the American Society of Hematology and National Institutes of Health. L.E.P. is an employee of Elevance Health; she has received funding from Sanofi for an unrelated study. J.D.L. has consulted or served on the advisory board for Eli Lilly and Company, Samsung Bioepis, UCB, Bristol-Myers Squibb, Nestlé Health Science, Merck, Celgene, Janssen Pharmaceuticals, Bridge Biotherapeutics, Entasis Therapeutics, AbbVie, Pfizer, Gilead, Galapagos, Sanofi, Arena Pharmaceuticals, Protagonist Therapeutics, Amgen, and Scipher Medicine; has received research funding from Nestlé Health Science, Takeda, Janssen Pharmaceuticals, and AbbVie; has received educational grants from Takeda and Janssen; has performed legal work on behalf of generic manufacturers of ranitidine, including L. Perrigo Company, Glenmark Pharmaceuticals Inc, Amneal Pharmaceuticals LLC, Aurobindo Pharma USA, Dr. Reddy’s Laboratories, Novitium Pharma, Ranbaxy Inc, and Sun Pharmaceutical Industries, Strides Pharma, and Wockhardt USA LLC; and owns stock in Dark Canyon Labs. M.J.-F.’s employer (Center for Pharmacoepidemiology, Department of Epidemiology, University of North Carolina at Chapel Hill) has collaborative agreements AbbVie, Astellas, Boehringer Ingelheim, GlaxoSmithKline, Sarepta, Takeda, and UCB Biosciences, and she has received salary support to as Center Director. M.D.K. has consulted for AbbVie and Lilly; is a shareholder in Johnson & Johnson; and has received research support from Janssen and AbbVie. The other authors report no potential conflicts of interest.

References

    1. Long MD, Hutfless S, Kappelman MD, et al. . Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2014;20(2):398-415. - PMC - PubMed
    1. Johnson EK, Nelson CP.. Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol. 2013;190(1):17-18. - PMC - PubMed
    1. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J.. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103(8):1998-2006. - PubMed
    1. Bernstein CN, Wajda A, Svenson LW, et al. . The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006;101(7):1559-1568. - PubMed
    1. Rezaie A, Quan H, Fedorak RN, Panaccione R, Hilsden RJ.. Development and validation of an administrative case definition for inflammatory bowel diseases. Can J Gastroenterol. 2012;26(10):711-717. - PMC - PubMed

Publication types